Autres langues BioPorto A/S

Actions

Marché Fermé - Nasdaq Copenhagen Autres places de cotation 17:20:00 16/07/2024			Varia. 5j.	Varia. 1 janv.
2,23 ^DKK	+0,45 %		+7,21 %	+6,70 %

18/06	BioPorto lève 81 millions de couronnes danoises pour financer des essais cliniques	MT
30/05	BioPorto A/S nomme Niels Høy Nielsen membre de l'équipe de direction, à compter du 1er août 2024	CI

Grant of Warrants	04/07
Immundiagnostik, Inc. Partners with BioPorto Diagnostics A/S to Expand Renal Research Offering	01/07
BioPorto A/S : Managers' transactions	24/06
Managers’ transactions	24/06
Changes of number of shares and votes in BioPorto A/S	24/06
BioPorto to Raise DKK81 Million to Fund Clinical Trials	18/06
Private placement of 50,000,000 new shares oversubscribed - gross proceeds of DKK 81.4 million, corresponding to USD 11.7 million, to BioPorto A/S.	18/06
BioPorto A/S initiates a private placement of 50,000,000 new shares at market price.	17/06
BioPorto A/S Appoints Chief Financial Officer	30/05
BioPorto A/S Appoints Niels Høy Nielsen as Member of the Executive Management Team, Effective August 1, 2024	30/05
BioPorto A/S Appoints Niels Høy Nielsen as Chief Financial Officer, Effective August 1, 2024	30/05
First Quarter 2024: Strong growth in US sales of The NGAL Test	08/05
BioPorto A/S Reports Earnings Results for the First Quarter Ended March 31, 2024	08/05
Bioporto A/S Provides Earnings Guidance for 2024	08/05
Resolutions of Annual Geneal Meeting	30/04
Grant of warrants	23/04
BioPorto Names New Chief Legal Officer	10/04
BioPorto A/S Appoints Chief Legal Officer	10/04
Bioporto A/S Appoints Gry Louise Husby Larsen as Chief Legal Officer and Member of the Executive Management Team, Effective as of April 15, 2024	10/04
New Board Candidate for the upcoming Annual Geneal Meeting	05/04

Aucun résultat pour cette recherche